NASDAQ:BPTSY Biophytis (BPTSY) Stock Price, News & Analysis $0.25 0.00 (0.00%) As of 09/22/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC Filings About Biophytis Stock (NASDAQ:BPTSY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Biophytis alerts:Sign Up Key Stats Today's Range$0.25▼$0.2550-Day Range$0.25▼$0.2552-Week Range$0.00▼$2.08VolumeN/AAverage Volume1,154 shsMarket Capitalization$586.50 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Biophytis S.A. is a France-based clinical-stage biotechnology company focused on developing therapies for diseases associated with aging and physical decline. Its research programs target conditions affecting muscle function, respiratory health and other age-related disorders. The company’s leading drug candidate is Sarconeos (BIO101), an orally administered small molecule being investigated for sarcopenia, a condition characterized by the progressive loss of muscle mass and strength. Biophytis has also evaluated BIO101 in other settings, including severe respiratory complications associated with COVID-19 and Duchenne muscular dystrophy. The company’s pipeline is based in part on bioactive compounds derived from plants. Biophytis was founded in France in 2006 and conducts research and clinical-development activities in Europe and the United States. The company has been led by co-founder Stanislas Veillet, who serves as chief executive officer. As a development-stage biotechnology company, Biophytis’ activities are centered on advancing its candidates through clinical testing and regulatory evaluation.AI Generated. May Contain Errors. Read More Receive BPTSY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biophytis and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BPTSY Stock News HeadlinesBiophytis Files 2025 Annual Financial Report with U.S. SECAugust 27, 2026 | tipranks.comBiophytis-LynxKite Alliance Expands to Turbocharge AI-driven drug discovery for next generation longevity therapeuticsMarch 13, 2026 | tmcnet.comSee More Headlines BPTSY Stock Analysis - Frequently Asked Questions How have BPTSY shares performed this year? Biophytis' stock was trading at $0.0110 on January 1st, 2026. Since then, BPTSY stock has increased by 2,172.7% and is now trading at $0.25. How do I buy shares of Biophytis? Shares of BPTSY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today9/24/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:BPTSY CIK1768946 Webwww.biophytis.com Phone33-1-44-27-23-00FaxN/AEmployees30Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.41 Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($16.18) per share Price / Book-0.02Miscellaneous Outstanding Shares2,346,000Free Float338,000Market Cap$586.50 thousand OptionableN/A Beta2.46 The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:BPTSY) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThe Pentagon Has 120 Days to Solve This Critical Mineral ProblemChina controls roughly 80% of the world's tungsten supply, and new Pentagon sourcing restrictions take effect ...The Tomorrow Investor | SponsoredThey're shrinking your dollars every single monthSince 2020, the dollar has lost roughly a quarter of its buying power. A $500,000 nest egg today buys about wh...American Alternative | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredWhy I believe the AI market will split in Q4Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...The Oxford Club | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredCongress Passes Landmark Digital Asset Law Wall Street Is WatchingThe House passed the Digital Asset Market Clarity Act 294 to 134, creating the most comprehensive financial te...Awesomely | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biophytis S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biophytis With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
